anti-MAGE-A4/A8 CAR T-cell gene therapy (Inmatics)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-MAGE-A4/A8 CAR T-cell gene therapy (Inmatics)
Drug Alias NameCAR T-cell therapy (immatics)IMA-201 (immatics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMelanoma-associated antigen 8 modulatorsImmunostimulantsMelanoma-associated antigen 4 modulators +[4] 
TargetsMelanoma-associated antigen 8Melanoma-associated antigen 4
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmatics NV
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb CompanyImmatics NV
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A